Skip to main content
SpringerLink
Log in

Breast Cancer Prevention Trials Using Retinoids

  • Published:
Journal of Mammary Gland Biology and Neoplasia Aims and scope Submit manuscript

Abstract

Retinoids have been studied as chemopreventive agents in clinical trials. Given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide has extensively been investigated because of its favorable toxicological profile in humans. In a phase III secondary prevention trial, fenretinide showed a trend to a reduction of second breast malignancies in premenopausal women but not in postmenopausal women. This pattern was associated with a similar modulation of circulating IGF-I. A trend towards a reduction of ovarian cancer was also noted. Biomarker studies of fenretinide or novel selective retinoids alone and in combination with different nuclear receptor ligands are being conducted. These studies provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women, and offer clues as to both the pathophysiology of carcinogenesis and the drug mechanisms of action, and help select new compounds and doses for testing in large randomized studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. P. Chambon (1996). A decade of molecular biology of retinoic acid receptors. FASEB J. 10:940-954.

    PubMed  Google Scholar 

  2. M. J. Spinella and E. Dmitrovsky (2000). Aberrant retinoid signaling and breast cancer: The view from outside the nucleus. J. Natl. Cancer Inst. 92:438-440.

    PubMed  Google Scholar 

  3. A. Fanjul, M. I. Dawson, P. D. Hobbs, L. Jong, J. F. Cameron, E. Harlev, G. Graupner, X. P. Lu, and M. Pfahl (1994). A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372:107-111.

    PubMed  Google Scholar 

  4. S. Y. Sun and R. Lotan (2002). Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hematol 41:41-55.

    PubMed  Google Scholar 

  5. S. M. Lippman, J. J. Lee, and A. L. Sabichi (1998). Cancer chemoprevention: Progress and promise. J. Natl. Cancer Inst. 90:1514-1528.

    PubMed  Google Scholar 

  6. M. B. Sporn, N. M. Dunlop, D. L. Newton, and J. M. Smith (1976). Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 35:1332-1338.

    PubMed  Google Scholar 

  7. R. C. Moon, H. J. Thompson, P. J. Becci, C. J. Grubbs, R. J. Gander, D. L. Newton, et al. (1979). N-(4-Hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 39:1339-1346.

    PubMed  Google Scholar 

  8. G. J. Kelloff, J. A. Crowell, C. W. Boone, V. E. Steele R. A. Lubet, P. Greenwald, et al. (1994). Clinical development plan: N-(4-hydroxyphenyl)retinamide. J. Cell Biochem. Suppl. 20:176-196.

    PubMed  Google Scholar 

  9. M. S. Sheikh, Z. M. Shao, X. S. Li, J. V. Ordonez, B. A. Conley, S. Wu, et al. (1995). N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16:2477-2486.

    PubMed  Google Scholar 

  10. A. N. Fanjul, D. Delia, M. A. Pierotti, D. Rideout, J. Q. Yu, M. Pfahl, et al. (1996). 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J. Biol. Chem. 271:22441-22446.

    PubMed  Google Scholar 

  11. S. Y. Sun, W. Li, P. Yue, S. M. Lippman, W. K. Hong, and R. Lotan (1999). Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res. 59:2493-2498.

    PubMed  Google Scholar 

  12. R Lotan (1995). Retinoids and apoptosis: Implications for cancer chemoprevention and therapy. J. Natl. Cancer Inst. 87:1655-1657.

    PubMed  Google Scholar 

  13. N. Oridate, S. Suzuki, M. Higuchi, M. F. Mitchell, W. K. Hong, and R. Lotan (1997). Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J. Natl. Cancer Inst. 89:1191-1198.

    PubMed  Google Scholar 

  14. A. L. Sabichi, D. T. Hendricks, M. A. Bober, and M. J. Birrer (1998). Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J. Natl. Cancer Inst. 90:597-605.

    PubMed  Google Scholar 

  15. B. S. Herbert, B. G. Sanders, and K. Kline (1999). N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells. Nutr. Cancer 34:121-132.

    PubMed  Google Scholar 

  16. S. Y. Sun, P. Yue, and R. Lotan (1999). Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol. Pharmacol. 55:403-410.

    PubMed  Google Scholar 

  17. A. Bednarek, A. Shilkaitis, A. Green, R. Lubet, G. Kelloff, K. Christov, et al. (1999). Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors. Carcinogenesis 20:879-883.

    PubMed  Google Scholar 

  18. H. Jinno, M. G. Steiner, R. G. Mehta, M. P. Osborne, and N. T. Telang (1999). Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide. Carcinogenesis 20:229-236.

    PubMed  Google Scholar 

  19. G. N. Rao, E. Ney, and R. A. Herbert (1998). Effect of retinoid analogues on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res. Treat 48:265-271.

    PubMed  Google Scholar 

  20. R. G. Mehta, R. C. Moon, M. Hawthorne, F. Formelli, and A. Costa (1991). Distribution of fenretinide in the mammary gland of breast cancer patients. Eur. J. Cancer 27:138-141.

    PubMed  Google Scholar 

  21. P. Broet, de la A. Rochefordiere, S. M. Schooll, A. Fourquet, V. Mosseri, J. C. Durand, et al. (1995). Contralateral breast cancer: Annual incidence and risk parameters. J. Clin. Oncol. 13:1578-1583.

    PubMed  Google Scholar 

  22. A. Costa, W. Malone, M. Perloff, F. Buranelli, T. Campa, G. Dossena, et al. (1989). Tolerability of the synthetic retinoid Fenretinide (HPR). Eur. J. Cancer Clin. Oncol 25:805-808.

    PubMed  Google Scholar 

  23. F. Formelli, R. Carsana, A. Costa, F. Buranelli, T. Campa, G. Dossena, et al. (1989). Plasma retinol level reduction by the synthetic retinoid fenretinide: A one year follow-up study of breast cancer patients. Cancer Res. 49:6149-6152.

    PubMed  Google Scholar 

  24. R. Berni and F. Formelli (1992). In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett. 308:43-45.

    PubMed  Google Scholar 

  25. K. C. Lewis, L. A. Zech, and J. M. Phang (1996). Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye. Eur. J. Cancer 32A:1803-1808.

    PubMed  Google Scholar 

  26. F. Formelli, M. Clerici, T. Campa, Di M. G. Mauro, A. Magni, G. Mascotti et al. (1993). Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J. Clin. Oncol. 11:2036-2042.

    PubMed  Google Scholar 

  27. G. De Palo, T. Camerini, E. Marubini, A. Costa, F. Formelli, M. Del Vecchio et al. (1997). Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori 83:884-894.

    PubMed  Google Scholar 

  28. U. Veronesi, G. De Palo, E. Marubini, A. Costa, F Formelli, L Mariani et al. (1999). Randomized trial of fenretinide to preven second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. 91:1847-1856.

    PubMed  Google Scholar 

  29. G. De Palo, U. Veronesi, T. Camerini, F. Formelli, G. Mascotti, C. Boni et al. (1995). Can fenretinide protect women against ovarian cancer? J. Natl. Cancer Inst. 87:146-147.

    PubMed  Google Scholar 

  30. G. De Palo, L. Mariani, T. Camerini, E. Marubini, F. Formelli, B. Pasini, et al. (2002). Effect of fenretinide on ovarian carcinoma occurrence. Gynecol. Oncol. 86:24-27.

    PubMed  Google Scholar 

  31. U. Veronesi and A. Decensi (2001). Retinoids for ovarian cancer prevention: Laboratory data set the stage for thoughtful clinical trials. J. Natl. Cancer Inst. 93:486-488.

    PubMed  Google Scholar 

  32. M. Widschwendter, J. Berger, G. Daxenbichler, E. Muller-Holzner, A. Widschwendter, A. Mayr et al. (1997). Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res. 57:4158-4161.

    PubMed  Google Scholar 

  33. R. Torrisi, F. Pensa, M. A. Orengo, E. Catsafados, P. Ponzani, F. Boccardo, et al. (1993). The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res. 53:4769-4771.

    PubMed  Google Scholar 

  34. R. Torrisi, S. Parodi, V. Fontana, F. Pensa, C. Casella, A. Barreca, et al. (1998). Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int. J. Cancer 76:787-790.

    PubMed  Google Scholar 

  35. R. E. Favoni, A. de Cupis, S. Bruno, D. Yee, A. Ferrera, P. Pirani et al. (1998). Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br. J. Cancer 77:2138-2147.

    PubMed  Google Scholar 

  36. M. Pollak (2000). Insulin-like growth factor physiology and cancer risk. Eur. J. Cancer 36:1224-1228.

    PubMed  Google Scholar 

  37. H. Yu and T. Rohan (2000). Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. 92:1472-1489.

    PubMed  Google Scholar 

  38. Z. P. Gill, C. M. Perks, P. V. Newcomb, and J. M. Holly (1997). Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J. Biol. Chem. 272:25602-25607.

    PubMed  Google Scholar 

  39. R. Rajah, B. Valentinis, and P. Cohen (1997). Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53-and IGF-independent mechanism. J. Biol. Chem. 272:12181-12188.

    PubMed  Google Scholar 

  40. J. M. Chan, M. J. Stampfer, E. Giovannucci, P. H. Gann, J. Ma, P. Wilkinson, et al. (1998). Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study. Science 279:563-566.

    PubMed  Google Scholar 

  41. S. E. Hankinson, W. C. Willett, G. A. Colditz, D. J. Hunter, D. S. Michaud, B. Deroo, et al. (1998). Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396.

    PubMed  Google Scholar 

  42. J. Ma M. N. Pollak, E. Giovannucci, J. M. Chan, Y. Tao, Ch. Hennekens, et al. (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer. Inst. 91:620-625.

    PubMed  Google Scholar 

  43. E. Giovannucci, M. N. Pollak, E. A. Platz, W. C. Willett, M. J. Stampfer, N. Majeed, et al. (2000). A prospective study of plasma insulin-like growth factor-1 and binding prtein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol. Biomarkers Prev. 9:345-349.

    PubMed  Google Scholar 

  44. S. J. London, J. M. Yuan, G. S. Travlos, Y. T. Gao, R. E. Wilson, R. K. Rose, et al. (2002). Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J. Natl. Cancer Inst. 94:749-754.

    PubMed  Google Scholar 

  45. P. Toniolo, P. F. Bruning, A. Akhmedkhanov, J. M. Bonfrer, K. L. Koenig, A. Lukanova, et al. (2000). Serum insulin-like growth factor-I and breast cancer. Int. J. Cancer 88:828-832.

    PubMed  Google Scholar 

  46. R. B. Clarke, A. Howell, and E. Anderson (1997). Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br. J. Cancer 75:251-257.

    PubMed  Google Scholar 

  47. A. Lai, B. Sarcevic, O. W. Prall, and R. L. Sutherland (2001). Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21 (WAF1/Cip1). J. Biol. Chem. 276:25823-25833.

    PubMed  Google Scholar 

  48. G. T. Budd, P. C. Adamson, M. Gupta, P. Homayoun, S. K. Sandstrom, R. F. Murphy, et al. (1998). Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin. Cancer Res. 4:635-642.

    PubMed  Google Scholar 

  49. A. Decensi, H. Johansson, R. Micelli, L. Mariani, T. Camerini, E. Cavadini, et al. (2001). Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer. Cancer Epidemiol. Biomarkers Prev. 10:1047-1053.

    PubMed  Google Scholar 

  50. B. Fisher, J. Dignam, N. Wolmark, D. L. Wickerham, E. R. Fisher, E. Mamounas, et al. (1999). Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000.

    PubMed  Google Scholar 

  51. Z. Li, M. P. Meredith, and M. S. Hoseyni (2001). A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat. Med. 20:3175-3188.

    PubMed  Google Scholar 

  52. L. S. Freedman, B. I. Graubard, and A. Schatzkin (1992). Statistical validation of intermediate endpoints for chronic diseases. Stat. Med. 11:167-178.

    PubMed  Google Scholar 

  53. T. Camerini, L. Mariani, G. De Palo, E. Marubini, M. G. Di Mauro, A. Decensi, et al. (2001). Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J. Clin. Oncol. 19:1664-1670.

    PubMed  Google Scholar 

  54. A. Decensi, R. Torrisi, A. Gozza, G. Severi, G. Bertelli, V. Fontana, et al. (1999). Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer. Breast Cancer Res. Treat. 53:145-151.

    PubMed  Google Scholar 

  55. A. Decensi, R. Torrisi, A. Polizzi, R. Gesi, V. Brezzo, M. Rolando, et al. (1994). Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J. Natl. Cancer Inst. 86:105-110.

    PubMed  Google Scholar 

  56. R. C. Caruso, J. Zujewski, F. Iwata, M. J. Podgor, B. A. Conley, L. M. Ayres, et al. (1998). Effects of fenretinide (4-HPR) on dark adapation. Arch. Ophtalmol. 116:759-763.

    Google Scholar 

  57. R. Torrisi, S. Parodi, V. Fontana, G. Rondanina, F. Formelli, A. Costa, et al. (1994). Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 3:507-510.

    Google Scholar 

  58. T. A. Ratko, C. J. Detrisac, N. M. Dinger, C. F. Thomas, G. J. Kelloff, and R. C. Moon (1989). Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. 49:4472-4476.

    PubMed  Google Scholar 

  59. M. A. Anzano, C. W. Peer, J. M. Smith, L. T. Mullen, M. W. Shrader, D. L. Logsdon, et al. (1996). Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. 88:123-125.

    PubMed  Google Scholar 

  60. J. Zujewski, L. Pai, L. Wakefield, R. Giusti, F. A. Dorr, C. Flanders et al. (1999). Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res. Treat 57:277-283.

    PubMed  Google Scholar 

  61. B. Conley, J. O'Shaughnessy, S. Prindiville, J. Lawrence, C. Chow, E. Jones, et al. (2000). Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J. Clin. Oncol. 18:275-283.

    PubMed  Google Scholar 

  62. M. A. Cobleigh, R. Gray, M. Graham, L. Norton, S. Martino, G. T. Budd, J. N. Ingle, N. E. Davidson, and W. C. Wood (2000). Fenretinide (FEN) Vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group phase III intergroup trial (EB193, INT-0151). Proc. Am. Soc. Clin. Oncol. 19, 86. (Abstract).

    Google Scholar 

  63. S. E. Singletary, E. N. Atkinson, A. Hoque, N. Sneige, A. A. Sahin, H. A. J. Fritsche, et al. (2000). Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin. Cancer Res. 8:2835-2842.

    Google Scholar 

  64. T. C. Hillard, S. J. Whitcroft, M. S. Marsh, M. C. Ellerington, B. Lees, M. I. Whitehead et al. (1994). Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos. Int. 4:341-348.

    PubMed  Google Scholar 

  65. A. Decensi, U. Omodei, C. Robertson, B. Bonanni, A. Guerrieri-Gonzaga, F. Ramazzotto, H. Johansson, S. Mora, M. T. Sandri, M. Cazzaniga, M. Franchi, and S. Pecurelli (2002). Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in a retinoid-placebo trial in healthy women. Circulation.

  66. B. W. Walsh, S. Paul, R. A. Wild, R. A. Dean, R. P. Tracy, D. A. Cox, et al. (2000). The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J. Clin. Endocrinol. Metab. 85:214-218.

    PubMed  Google Scholar 

  67. P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342:836-843.

    PubMed  Google Scholar 

  68. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613.

    PubMed  Google Scholar 

  69. A. Koj, A. Guzdek, T. Nakamura, and T. Kordula (1995). Hepatocyte growth factor and retinoic acid exert opposite effects on synthesis of type 1 and type 2 acute phase proteins in rat hepatoma cells. Int. J. Biochem. Cell Biol. 27:39-46.

    PubMed  Google Scholar 

  70. A. A. Levin, L. J. Sturzenbecker, S. Kazmer, T. Bosakowski, C. Huselton, G. Allenby et al. (1992). 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 355:359-361.

    PubMed  Google Scholar 

  71. T. H. Bugge, J. Pohl, O. Lonnoy, and H. G. Stunnenberg (1992). RXR alpha, a promiscuous partner of retinoic acid and thyroid hormone receptors. EMBO J. 11:1409-1418.

    PubMed  Google Scholar 

  72. S. A. Kliewer, K. Umesono, D. J. Mangelsdorf, and R. M. Evans (1992). Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355:446-449.

    PubMed  Google Scholar 

  73. K. L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, and J. A. Gustafsson (1993). Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc. Natl. Acad. Sci. USA 90:1440-1444.

    PubMed  Google Scholar 

  74. R. C. Moon, G. J. Kelloff, C. J. Detrisac, V. E. Steele, C. F. Thomas, and C. C. Sigma (1992). Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res. 12:1147-1153.

    PubMed  Google Scholar 

  75. M. A. Anzano, S. W. Byers, J. M. Smith, C. W. Peer, L. T. Mullen, C. C. Brown, et al. (1994). Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54:4614-4617.

    PubMed  Google Scholar 

  76. J. A. Lawrence, P. C. Adamson, R. Caruso, C. Chow, D. Kleiner, R. F. Murphy, et al. (2001). Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations. J. Clin. Oncol. 19:2754-2763.

    PubMed  Google Scholar 

  77. K. Wu, H. T. Kim, J. L. Rodriquez, S. G. Hilsenbeck, S. K. Mohsin, X. C. Xu, et al. (2002). Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol. Biomarkers Prev. 11:467-474.

    PubMed  Google Scholar 

  78. K. Wu, Y. Zhang, X. C. Xu, J. Hill, J. Celestino, H. T. Kim, et al. (2002). The retinoid X receptor-selective retinoid, LGD 1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 62:6376-6380.

    PubMed  Google Scholar 

  79. M. Duvic, K. Hymes, P. Heald, D. Breneman, A. G. Martin, P. Myskowski, et al. (2001). Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J. Clin. Oncol. 19:2456-2471.

    PubMed  Google Scholar 

  80. F. J. Esteva, J. Glaspy, S. Baidas, L. Laufman, L. Hutchins, M. Dickler, D. Tripathy, R. Cohen, A. De Michele, R. C. Yocum, C. K. Osborne, D. F. Hayes, G. N. Hortobagyi, E. Winer, and G. D. Dematri (2003). Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J. Clin.

Download references

Author information

Authors and Affiliations

  1. Division of Chemoprevention, European Institute of Oncology, Milan, Italy

    Andrea Decensi, Davide Serrano, Bernardo Bonanni, Massimiliano Cazzaniga & Aliana Guerrieri-Gonzaga

Authors
  1. Andrea Decensi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davide Serrano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernardo Bonanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Massimiliano Cazzaniga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aliana Guerrieri-Gonzaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Decensi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Decensi, A., Serrano, D., Bonanni, B. et al. Breast Cancer Prevention Trials Using Retinoids. J Mammary Gland Biol Neoplasia 8, 19–30 (2003). https://doi.org/10.1023/A:1025779120649

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1025779120649

Search

Navigation